Travere Therapeutics
3611 Valley Centre Drive
Suite 300
San Diego
California
92130
United States
Tel: 888-969-7879
Website: https://travere.com/
353 articles about Travere Therapeutics
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 11, 2022
8/11/2022
Travere Therapeutics, Inc. announced that on August 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants to 29 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 101,500 shares of its common stock.
-
Travere Therapeutics Provides Regulatory Updates on its Development Programs
8/3/2022
Travere Therapeutics, Inc. provided regulatory updates for its sparsentan programs in IgA nephropathy and focal segmental glomerulosclerosis, as well as its pegtibatinase program for classical homocystinuria.
-
Travere Therapeutics to Report Second Quarter 2022 Financial Results
7/28/2022
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022 before the open of the U.S. financial markets.
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 12, 2022
7/12/2022
Travere Therapeutics, Inc. announced that on July 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants to 43 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 120,700 shares of its common stock.
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 14, 2022
6/14/2022
Travere Therapeutics, Inc. announced that on June 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants to ten new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 48,750 shares of its common stock.
-
Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference
6/2/2022
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET.
-
Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress
5/17/2022
Travere Therapeutics, Inc. announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal Phase 3 PROTECT and DUPLEX studies of sparsentan in IgA nephropathy and focal segmental glomerulosclerosis, respectively, at the 59th European Renal Association Congress.
-
Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
5/16/2022
Travere Therapeutics, Inc. announced the U.S. Food and Drug Administration has accepted and granted Priority Review of its New Drug Application under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy.
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 11, 2022
5/11/2022
Travere Therapeutics, Inc. announced that on May 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants to 15 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 91,000 shares of its common stock.
-
Travere Therapeutics Reports First Quarter 2022 Financial Results
5/5/2022
Travere Therapeutics, Inc. reported its first quarter 2022 financial results and provided a corporate update.
-
Travere Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
5/3/2022
Travere Therapeutics, Inc. announced that Eric Dube, Ph.D., president and chief executive officer, will present at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022, at 4:00 p.m. PT.
-
Travere Therapeutics to Report First Quarter 2022 Financial Results
4/28/2022
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the close of the U.S. financial markets.
-
Travere Therapeutics Announces Plan for Chief Financial Officer Transition
4/20/2022
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that its chief financial officer Laura Clague, CPA, will retire after serving in this role for the past seven years.
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 12, 2022
4/12/2022
Travere Therapeutics, Inc. announced that on April 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants to 13 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 51,750 shares of its common stock.
-
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 43rd Annual Meeting and the Genetic Metabolic Dieticians International Conference 2022
4/6/2022
Travere Therapeutics, Inc. announced that the Company will present data from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria, at the Society for Inherited Metabolic Disorders 43rd Annual Meeting, and the 2022 Genetic Metabolic Dieticians International Conference.
-
Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
3/21/2022
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 14, 2022
3/14/2022
Travere Therapeutics, Inc. announced that on March 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 58,000 shares of its common stock to eight new employees, consisting of inducement stock options to purchase an aggregate of 25,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 33,000 shares of its common stock.
-
Travere Prices Upsized $275 Million Convertible Senior Notes Offering
3/9/2022
Travere Therapeutics, Inc. announced the pricing of its underwritten offering of $275 million aggregate principal amount of 2.25% convertible senior notes due 2029.
-
Travere Announces Proposed Convertible Senior Notes Offering - Mar 08, 2022
3/8/2022
Travere Therapeutics, Inc. announced its intention to offer, subject to market and other conditions, $250 million aggregate principal amount of convertible senior notes due 2029 in an underwritten offering.
-
Travere Therapeutics to Present at the Barclays Global Healthcare Conference - Mar 03, 2022
3/3/2022
Travere Therapeutics, Inc. announced that Company management will present at the Barclays Global Healthcare Conference on Thursday, March 17, 2022 at 8:30 a.m. ET.